DUBLIN, Ireland — Adapt Pharma presented results of a survey conducted with police and community organizations describing real-world experiences and outcomes with the FDA-approved 4mg naloxone nasal spray formulation.
The survey results were presented as a poster, titled “Use of Naloxone Nasal Spray in the Community Setting: a Survey of Use by Community Organizations,” at the annual American Academy of Pain Medicine in Orlando, Fla.
The survey collected case data and examined the outcomes of attempted opioid-related overdose reversals reported by first responders and community health organizations, where Narcan Nasal Spray 4mg was administered. Participating organizations provided data on several outcome measures including reversal outcomes, agents involved in overdose and observed events.
Key findings of the survey include:
- Reversal outcomes: Of the 261 attempted reversals, 245 recorded a known clinical outcome. Of the reported outcomes, 98.8 percent (242/245) of the attempted opioid-related overdose reversals were reported to be successful following administration of Narcan.
- Agents involved in overdose: The presumed substance involved in the reported opioid-related overdose cases were heroin (95.4 percent) and fentanyl (5.2 percent).
- Time-to-response: The time-to-response reported after Narcan administration was less than five minutes in most cases (73.5 percent; 125/170 cases), consistent with intramuscular naloxone formulations.
- Observed events: Of the 261 attempted reversals, 196 recorded information on observed events. Of these observed events, 14.3 percent (28/196) reported withdrawal, 10.2 percent (20/196) reported nausea or vomiting, and 8.7 percent (17/196) reported irritability or anger. No new safety issues were identified.